Osaic Holdings Inc. Grows Position in IQVIA Holdings Inc. $IQV

by · The Markets Daily

Osaic Holdings Inc. raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 32.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 71,103 shares of the medical research company’s stock after purchasing an additional 17,217 shares during the period. Osaic Holdings Inc.’s holdings in IQVIA were worth $11,233,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of IQV. Everpar Advisors LLC increased its holdings in IQVIA by 4.6% during the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after buying an additional 62 shares during the period. Private Trust Co. NA boosted its position in IQVIA by 12.5% during the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 67 shares in the last quarter. E Fund Management Co. Ltd. increased its holdings in shares of IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 74 shares during the period. Penserra Capital Management LLC raised its position in shares of IQVIA by 10.3% in the 2nd quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock worth $151,000 after acquiring an additional 90 shares in the last quarter. Finally, Forte Capital LLC ADV lifted its stake in shares of IQVIA by 0.3% during the 2nd quarter. Forte Capital LLC ADV now owns 26,809 shares of the medical research company’s stock worth $4,225,000 after purchasing an additional 92 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Trading Down 0.8%

Shares of IQVIA stock opened at $220.75 on Friday. The firm’s 50 day simple moving average is $219.06 and its two-hundred day simple moving average is $192.18. The firm has a market capitalization of $37.59 billion, a price-to-earnings ratio of 30.28, a PEG ratio of 2.50 and a beta of 1.37. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $234.29. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same period in the previous year, the firm posted $2.84 earnings per share. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

IQV has been the topic of several analyst reports. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Barclays set a $230.00 price objective on shares of IQVIA in a research note on Monday. BMO Capital Markets began coverage on shares of IQVIA in a research note on Thursday, November 13th. They issued an “outperform” rating and a $260.00 target price for the company. Finally, Morgan Stanley upped their price target on IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $243.19.

Get Our Latest Stock Analysis on IQVIA

IQVIA Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Recommended Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).